WeightWatchers Clinic (Med+)vsFound Weight Loss Program

After an online health quiz, a board-certified clinician reviews your history via telehealth and, when appropriate, prescribes an FDA-approved GLP-1 such as semaglutide (Wegovy), tirzepatide (Zepbound), or liraglutide (Saxenda). These drugs mimic gut hormones that slow stomach emptying and curb appetite. WW's app, nutrition counseling, and GLP-1 Success Program run alongside to help you manage diet and side effects through dose titration.

After an online intake and Found's MetabolicPrint assessment, a licensed clinician reviews your profile and prescribes a GLP-1 when appropriate. Cash-pay plans include compounded semaglutide or tirzepatide; branded GLP-1s can be prescribed but are billed separately. These drugs act on GLP-1 (and, for tirzepatide, GIP) receptors to reduce appetite and slow gastric emptying. The Found app delivers behavioral coaching, an AI health companion, and community support throughout.

The underlying medications are the most effective pharmacotherapy available: in pivotal trials semaglutide 2.4mg produced roughly 15% mean weight loss (STEP 1) and tirzepatide up to about 21% (SURMOUNT-1). WeightWatchers reports members who engage with its GLP-1 Success Program average about 21% body-weight loss at 12 months, though company-reported figures should be read cautiously and individual results vary.

The GLP-1 actives Found uses are the same molecules studied in landmark trials, where semaglutide produced roughly 15% mean weight loss (STEP 1) and tirzepatide up to about 21% (SURMOUNT-1). However, compounded formulations are not FDA-approved and have not been individually tested for the brand-name trial endpoints, so results may differ. Individual results vary.

GLP-1 therapy commonly causes gastrointestinal effects (nausea, diarrhea, constipation, vomiting) that often ease as the dose is titrated slowly. Rare but serious risks include pancreatitis and gallbladder disease. This is educational information, not medical advice; discuss your history with the clinician.

GLP-1 medications commonly cause nausea, constipation, and diarrhea, usually most pronounced during dose increases. Serious but rare risks include pancreatitis and gallbladder disease. Because cash plans use compounded products, ask about the compounding pharmacy and ingredients. This is educational, not medical advice.

As of 2026, membership runs $25/mo for the first two months then $74/mo on a 12-month plan. Medication is billed separately and not included; uninsured branded GLP-1 costs can range from roughly $350 to $1,300/mo, so total spend depends heavily on coverage.

As of 2026, membership is advertised 'as low as $49/mo,' with a common 3-month Kickstart at first-month-free then $129/mo for self-pay members. Compounded GLP-1 is included in cash-pay plans; branded drugs cost extra. Kickstart excludes Medicare/Medicaid/TriCare enrollees.

Candidates complete an online health-history quiz; final suitability is decided in a telehealth consult with a board-certified clinician. GLP-1 prescribing generally follows label criteria (e.g., BMI 30+, or 27+ with a weight-related condition), but the clinician makes the determination.

Prospective members complete an online health quiz and metabolic assessment; a licensed clinician makes the final prescribing decision based on GLP-1 eligibility guidelines (typically BMI 30+, or 27+ with a related condition). Kickstart self-pay pricing is not available to those with in-network insurance or government plans.